325 related articles for article (PubMed ID: 33077895)
1. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
Reid Thompson W; Hornby B; Manuel R; Bradley E; Laux J; Carr J; Vernon HJ
Genet Med; 2021 Mar; 23(3):471-478. PubMed ID: 33077895
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
Thompson WR; Manuel R; Abbruscato A; Carr J; Campbell J; Hornby B; Vaz FM; Vernon HJ
Genet Med; 2024 Apr; 26(7):101138. PubMed ID: 38602181
[TBL] [Abstract][Full Text] [Related]
3. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
Hornby B; Thompson WR; Almuqbil M; Manuel R; Abbruscato A; Carr J; Vernon HJ
Orphanet J Rare Dis; 2022 Sep; 17(1):336. PubMed ID: 36056411
[TBL] [Abstract][Full Text] [Related]
4. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.
Van den Eynde J; Chinni B; Vernon H; Thompson WR; Hornby B; Kutty S; Manlhiot C
Orphanet J Rare Dis; 2023 Apr; 18(1):76. PubMed ID: 37041653
[TBL] [Abstract][Full Text] [Related]
5. Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.
Sabbah HN; Taylor C; Vernon HJ
Future Cardiol; 2023 Mar; 19(4):211-225. PubMed ID: 37325898
[TBL] [Abstract][Full Text] [Related]
6. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
Sabbah HN
Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
[TBL] [Abstract][Full Text] [Related]
7. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
[TBL] [Abstract][Full Text] [Related]
8. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.
Karaa A; Haas R; Goldstein A; Vockley J; Cohen BH
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):909-918. PubMed ID: 32096613
[TBL] [Abstract][Full Text] [Related]
9. Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.
Sabbah HN
Heart Fail Rev; 2022 Sep; 27(5):1911-1923. PubMed ID: 34623544
[TBL] [Abstract][Full Text] [Related]
10. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.
Karaa A; Haas R; Goldstein A; Vockley J; Weaver WD; Cohen BH
Neurology; 2018 Apr; 90(14):e1212-e1221. PubMed ID: 29500292
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
Karaa A; Bertini E; Carelli V; Cohen BH; Enns GM; Falk MJ; Goldstein A; Gorman GS; Haas R; Hirano M; Klopstock T; Koenig MK; Kornblum C; Lamperti C; Lehman A; Longo N; Molnar MJ; Parikh S; Phan H; Pitceathly RDS; Saneto R; Scaglia F; Servidei S; Tarnopolsky M; Toscano A; Van Hove JLK; Vissing J; Vockley J; Finman JS; Brown DA; Shiffer JA; Mancuso M;
Neurology; 2023 Jul; 101(3):e238-e252. PubMed ID: 37268435
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial dysfunctions in barth syndrome.
Ghosh S; Iadarola DM; Ball WB; Gohil VM
IUBMB Life; 2019 Jul; 71(7):791-801. PubMed ID: 30746873
[TBL] [Abstract][Full Text] [Related]
13. Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts.
Mejia EM; Zegallai H; Bouchard ED; Banerji V; Ravandi A; Hatch GM
J Biol Chem; 2018 May; 293(20):7564-7577. PubMed ID: 29563154
[TBL] [Abstract][Full Text] [Related]
14. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
[TBL] [Abstract][Full Text] [Related]
15. Barth syndrome in a female patient.
Cosson L; Toutain A; Simard G; Kulik W; Matyas G; Guichet A; Blasco H; Maakaroun-Vermesse Z; Vaillant MC; Le Caignec C; Chantepie A; Labarthe F
Mol Genet Metab; 2012 May; 106(1):115-20. PubMed ID: 22410210
[TBL] [Abstract][Full Text] [Related]
16. Interplay between cardiolipin and plasmalogens in Barth syndrome.
Bozelli JC; Epand RM
J Inherit Metab Dis; 2022 Jan; 45(1):99-110. PubMed ID: 34655242
[TBL] [Abstract][Full Text] [Related]
17. Functional exercise capacity, strength, balance and motion reaction time in Barth syndrome.
Hornby B; McClellan R; Buckley L; Carson K; Gooding T; Vernon HJ
Orphanet J Rare Dis; 2019 Jan; 14(1):37. PubMed ID: 30744648
[TBL] [Abstract][Full Text] [Related]
18. Development and content validity of the Barth Syndrome Symptom Assessment (BTHS-SA) for adolescents and adults.
Gwaltney C; Stokes J; Aiudi A; Mazar I; Ollis S; Love E; Shields A
Orphanet J Rare Dis; 2021 Jun; 16(1):264. PubMed ID: 34108006
[TBL] [Abstract][Full Text] [Related]
19. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.
Ikon N; Ryan RO
Lipids; 2017 Feb; 52(2):99-108. PubMed ID: 28070695
[TBL] [Abstract][Full Text] [Related]
20. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
